Xeris Pharmaceuticals granted fast track designation by FDA for novel concentrated diazepam formulation for injection

This article was originally published here

Xeris’ XP-0863 was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet Syndrome. The FDA’s Fast Track designation highlights

The post Xeris Pharmaceuticals granted fast track designation by FDA for novel concentrated diazepam formulation for injection appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply